Dermatan sulfate - Mediolanum

Drug Profile

Dermatan sulfate - Mediolanum

Alternative Names: Dermatan sulfate; MF 701; Mistral

Latest Information Update: 28 May 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mediolanum
  • Developer Medinfar; Mediolanum; Vecchi & C. Piam
  • Class Antithrombotics; Glycosaminoglycans; Small molecules
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Venous thromboembolism
  • Discontinued Heparin-induced thrombocytopenia and thrombosis syndrome; Thrombosis

Most Recent Events

  • 07 Dec 2001 Investigation in Heparin-induced thrombocytopenia and thrombosis syndrome in Italy (Injection)
  • 27 Sep 1999 Launched for Venous thromboembolism (Prevention) in Italy (Injection)
  • 27 Sep 1999 A clinical study has been added to the Thromboses pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top